Synthesis, Crystal Structure, and Spectral Characterization of Flumatinib Mesylate

REFERENCES

• Zimmermann , J. ; Buchdunger , E. ; Mett , H. ; Meyer , T. ; Lydon , N. B. ; Traxler , P. Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors . Bioorg. Med. Chem. Lett. 1996 , 6 , 1221 – 1226 .
   Web of Science ®Google Scholar
• Zimmermann , J. ; Buchdunger , E. ; Mett , H. ; Meyer , T. ; Lydon , N. B. Potent and selective inhibitors of the Abl-kinase:phenylamino-pyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 1997, 7, 187–192.
   Web of Science ®Google Scholar
• Gorre , M. E. ; Mohammed , M. ; Ellwood , K. ; Hsu , N. ; Paquette , R. ; Rao , P. N. ; Sawyers , C. L. Clinical resistance to STI571 cancer therapy caused by BCR/ABL gene mutation or amplification . Science 2001 , 293 , 876 – 880 .
   PubMed Web of Science ®Google Scholar
• von Bubnoff , N. ; Schneller , F. ; Peschel , C. ; Duyster , J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study . Lancet 2002 , 359 , 487 – 491 .
   PubMed Web of Science ®Google Scholar
• Branford , S. ; Rudzki , Z. ; Walsh , S. ; Parkinson , I. ; Grigg , A. ; Szer , J. ; Taylor , K. ; Herrmann , R. ; Seymour , J. F. ; Arthur , C. ; Joske , D. ; Lynch , K. ; Hughes , T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis . Blood 2003 , 102 , 276 – 283 .
   PubMed Web of Science ®Google Scholar
• Al-Ali , H. K. ; Heinrich , M. C. ; Lange , T. ; Krahl , R. ; Mueller , M. ; Muller , C. ; Niederwieser , D. ; Druker , B. J. ; Deininger , M. W. N. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib . Hematol. J. 2004 , 5 , 55 – 60 .
   PubMedGoogle Scholar
• Zhou , T. ; Parillon , L. ; Li , F. ; Wang , Y. ; Keats , J. ; Lamore , S. ; Xu , Q. ; Shakespeare , W. ; Dalgarno , D. ; Zhu , X. Crystal structure of the T315I mutant of Abl kinase . Chem. Biol. Drug Des. 2007 , 70 , 171 – 181 .
   PubMed Web of Science ®Google Scholar
• Dasmahapatra , G. ; Nguyen , T. K. ; Dent , P. ; Grant , S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate–resistant hematopoietic cells expressing mutant forms of Bcr/Abl . Leuk. Res. 2006 , 30 , 1263 – 1272 .
   PubMed Web of Science ®Google Scholar
• Jorgensen , H. G. ; Allan , E. K. ; Mountford , J. C. ; Richmond , L. ; Harrison , S. ; Elliott , M. A. ; Holyoake , T. L. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate . Exp. Hematol. 2005 , 33 , 1140 – 1146 .
   PubMed Web of Science ®Google Scholar
• Heaney , N. B. ; Holyoake , T. L. Therapeutic targets in chronic myeloid leukaemia . Hematol. Oncol. 2007 , 25 , 66 – 75 .
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob , S. W. ; Fendrich , G. ; Floersheimer , A. ; Furet , P. ; Liebetanz , J. ; Rummel , G. ; Rheinberger , P. ; Centeleghe , M. ; Fabbro , D. ; Manley , P. W. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia . Acta Cryst. 2007 , D63 , 80 – 93 .
   Web of Science ®Google Scholar
• Sun , P. ; Lu , A. ; Yang , B. ; Hu , C. Aminopyrimidine compounds and their salts: Process for preparation and pharmaceutical use thereof. WO Patent 2006/069525A1; July 6, 2006.
   Google Scholar
• Nagar , B. ; Bornmann , W. G. ; Pellicena , P. ; Schindler , T. ; Veach , D. R. ; Miller , W. T. ; Clarkson , B. ; Kuriyan , J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) . Cancer Res. 2002 , 62 , 4236 – 4243 .
   PubMed Web of Science ®Google Scholar
• Asaki , T. ; Sugiyama , Y. ; Hamamoto , T. ; Higashioka , M. ; Umehara , M. ; Naito , H. ; Niwa , T. Design and synthesis of 3-substituted benzamide derivativesas Bcr-Abl kinase inhibitors . Bioorg. Med. Chem. Lett. 2006 , 16 , 1421 – 1425 .
   PubMed Web of Science ®Google Scholar